Perhaps timely catching Reviva Pharmaceuticals Holdings Inc (RVPH) would be a good idea

With 0.92 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.09 million shares. The 52-week range on RVPH shows that it touched its highest point at $4.28 and its lowest point at $0.60 during that stretch. It currently has a 1-year price target of $12.14. Beta for the stock currently stands at -0.06.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RVPH was down-trending over the past week, with a drop of -9.38%, but this was down by -43.96% over a month. Three-month performance dropped to -7.20% while six-month performance fell -8.66%. The stock lost -69.63% in the past year, while it has lost -35.91% so far this year. A look at the trailing 12-month EPS for RVPH yields -1.11 with Next year EPS estimates of -0.84. For the next quarter, that number is -0.21. This implies an EPS growth rate of 40.26% for this year and 14.78% for next year.

Float and Shares Shorts:

At present, 46.58 million RVPH shares are outstanding with a float of 41.63 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RVPH since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.96539 being high and -$1.0162 being low. For RVPH, this leads to a yearly average estimate of -$0.98571. Based on analyst estimates, the high estimate for the next quarter is -$0.21 and the low estimate is -$0.24. The average estimate for the next quarter is thus -$0.23.